Tewari et al. (2016) reported that elevated MCP-1 levels were significantly associated with decreased breast cancer survival, and MCP-1, along with NF-κB and TAMs, was identified as a key determinant of poor prognosis and low survival; highlighting its potential as a prognostic marker [65]. The gene discussed is CCL2; the disease is breast carcinoma.